[1]王东东,李晓光.肝癌射频消融后肿瘤残余的研究现状与进展[J].介入放射学杂志,2019,28(08):800-804.
 WANG Dongdong,LI Xiaoguang..Residual tumor after radiofrequency ablation of hepatocellular carcinoma: its current situation and research progress[J].journal interventional radiology,2019,28(08):800-804.
点击复制

肝癌射频消融后肿瘤残余的研究现状与进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
28
期数:
2019年08期
页码:
800-804
栏目:
综述
出版日期:
2019-08-25

文章信息/Info

Title:
Residual tumor after radiofrequency ablation of hepatocellular carcinoma: its current situation and research progress
作者:
王东东 李晓光
Author(s):
WANG Dongdong LI Xiaoguang.
Peking Union Medical College & Chinese Academy of Medical Sciences, Minimally Invasive Therapies Center for Tumors in Beijing Hospital, National Center of Gerontology, Beijing 100061, China
关键词:
【关键词】 射频消融 肝癌 肿瘤残余
文献标志码:
A
摘要:
【摘要】 射频消融术(RFA)是一种原位灭活肝癌的微创治疗技术,在肝癌的治疗方面取得了普遍认可,已成为除外科手术、放疗和化疗外的另一有效疗法,尤其适用于高龄、体弱、肿瘤不易切除或合并其他严重疾病的患者。肝癌RFA治疗后,及时发现有无肿瘤残余决定了治疗效果和预后,具有重要意义。本文就肝癌RFA可能造成肿瘤残余危险因素、影像学评估方法、病理特征、免疫学特征和联合治疗方面进行综述。

参考文献/References:

[1] Poch FG, Rieder C, Ballhausen H, et al. The vascular cooling effect in hepatic multipolar radiofrequency ablation leads to incom-plete ablation ex vivo[J]. Int J Hyperthermia, 2016, 32: 749-756.
[2] Ringe KI, Lutat C, Rieder C, et al. Experimental evaluation of the heat sink effect in hepatic microwave ablation[J]. PLoS One, 2015, 10: e0134301.
[3] Zorbas G, Samaras T. A study of the sink effect by blood vessels in radiofrequency ablation[J]. Comput Biol Med, 2015, 57: 182-186.
[4] 翟渊鹏, 王海英, 王 雁, 等. 超声引导射频消融治疗老年肝癌的效果及肿瘤残留的危险因素[J]. 中国老年学杂志, 2017, 37: 2475-2477.
[5] 张俊超,林 苏,朱月永. 射频消融治疗临近特殊部位肝癌的并发症及预防[J]. 临床肝胆病杂志, 2017, 33: 969-973.
[6] 吴亚光,徐 建, 董雪娜, 等. 射频消融术治疗肝癌32例观察[J]. 山东医药, 2008, 48: 37-38.
[7] 花永强, 陈 颢, 孟志强, 等. 超声引导射频消融治疗肝脏恶性肿瘤302例肿瘤残留危险因素分析[J].中国癌症杂志,2014, 24: 119-127.
[8] 孙文兵. 重视病理性完全消融提高肝癌射频消融疗效[J]. 中华肝胆外科杂志, 2011, 17: 182-185.
[9] 孙文兵. 重视安全边界, 提高肝癌射频消融的疗效[J]. 肿瘤学杂志, 2010, 16: 520-522.
[10] 国家肿瘤微创治疗产业技术创新战略联盟专家委员会, 中国医师协会介入医师分会消融治疗专家工作指导委员会, 北京医师协会介入医师分会. 影像引导肝脏肿瘤热消融治疗技术临床规范化应用专家共识[J]. 中华医学杂志, 2017, 97: 2420-2424.
[11] 王健琳, 刘 颖, 范秋阳, 等. 兔肝VX2肿瘤RFA术后残余瘤的超声表现及新生血管的研究[J]. 中国临床医学影像杂志,2013, 24: 639-643.
[12] 钟文景, 罗葆明, 智 慧, 等. 容积超声造影对兔肝VX2肿瘤射频消融效果的评估[J]. 中华医学超声杂志?电子版, 2009, 6: 92-97.
[13] 徐守军, 杜端明, 刘鹏程, 等. 肝肿瘤射频消融术后CT表现及其临床意义[J]. 介入放射学杂志, 2014, 23: 69-73.
[14] 吴 钺, 张曦彤, 宋庆宏, 等. CT鉴别兔肝VX2肿瘤射频消融后残余瘤与炎症反应[J]. 实用肝脏病杂志, 2010, 13: 203-205.
[15] 张 翔, 白人驹, 丁建民, 等. 动态增强与灌注CT扫描对肝癌射频消融后疗效评价的临床研究[J].实用放射学杂志,2012, 28: 687-691.
[16] Li Y, Shi G, Wang S, et al. Iodine quantification with dual-energy CT: phantom study and preliminary experience with VX2 residual tumour in rabbits after radiofrequency ablation[J]. Br J Radiol, 2013, 86: 20130143.
[17] 曲金荣, 刘翠翠, 张宏凯, 等. CT和磁共振成像在肝细胞癌射频治疗后射频边缘评价中的作用[J].中国医学科学院学报,2012, 34: 480-485.
[18] 曲金荣, 骆俊朋, 刘翠翠, 等. 比较多层螺旋CT和3.0 T MR成像在肝细胞癌射频治疗疗效评价中的作用[J]. 中华放射学杂志, 2012, 46: 697-700.
[19] 胡 海, 杨东均, 王雪梅, 等. MRI评价肝癌热消融疗效的研究进展[J]. 放射学实践, 2015, 30: 885-887.
[20] 刘亚珍,曾 燕. 功能MRI评价肝癌微创治疗疗效的研究进展[J]. 国际医学放射学杂志, 2015, 38: 131-133.
[21] Mori K, Fukuda K, Asaoka H, et al. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran: feasibility study[J]. Radiology, 2009, 251: 557-565.
[22] Okubo H, Kokubu S, Komiyama M, et al. Radiofrequency ablation of hepatocellular carcinoma: the feasibility of magnetic resonance imaging with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid for evaluating the ablative margin[J]. Hepatol Res, 2010, 40: 1034-1041.
[23] 姚树展, 张成琪, 陈 静, 等. 18 F-脱氧葡萄糖结合PET-CT显像诊断肝恶性肿瘤[J]. 第一军医大学学报, 2003, 23: 1214-1216.
[24] Wang SB, Wu HB, Wang QS, et al. Combined early dynamic F-18-FDG PET/CT and conventional whole-body F-18-FDG PET/CT provide one- stop imaging for detecting hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2015, 39: 324-330.
[25] 杜端明, 邹英华, 刘鹏程, 等. MRI评价兔VX2肝癌射频消融后改变: 与病理对照[J]. 中国医学影像技术, 2010, 26:605-608.
[26] Polosukhin VV, Cates JM, Lawson WE, et al. Hypoxia-inducible factor-1 signalling promotes goblet cell hyperplasia in airway epithelium[J]. J Pathol, 2011, 224: 203-211.
[27] Tammali R, Saxena A, Srivastava SK. Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1 alpha(HIF-1 alpha) and vascular endothelial growth factor(VEGF)by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells[J]. J Biol Chem, 2011, 286: 24089-24100.
[28] Kong J, Kong LQ, Kong JE, et al. After insufficient radiofre-quency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma[J]. J Transl Med, 2012, 10: 230.
[29] 曾江正, 蔡兴锐, 黄 芬, 等. 体外不完全射频消融后肝癌细胞上皮-间质转化相关长链非编码RNA差异表达[J]. 介入放射学杂志, 2017, 26: 823-829.
[30] Obara K, Matsumoto N, Okamoto M, et al. Insufficient radiofre-quency ablation therapy may induce further malignant transfor-mation of hepatocellular carcinoma[J]. Hepatol Int, 2008, 2: 116-123.
[31] Kong J, Kong J, Pan B, et al. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA[J]. PLoS One, 2012, 7: e37266.
[32] Yamada S, Utsunomiya T, Morine Y, et al. Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy[J]. Ann Surg Oncol, 2014, 21: S436-S442.
[33] Ke S, Ding XM, Kong J, et al. Low temperature of radiofre-quency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma[J]. J Transl Med, 2010, 8: 73.
[34] Zhao Z, Wu JY, Liu XD, et al. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy[J]. Cancer Lett, 2018, 421: 73-81.
[35] Dong S, Kong J, Kong F, et al. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways[J]. J Transl Med, 2013, 11: 273.
[36] Zhang N, Ma D, Wang L, et al. Insufficient radiofrequency ablation treated hepatocellular carcinoma cells promote metastasis by up-regulation ITGB3[J]. J Cancer, 2017, 8: 3742-3754.
[37] Zhang N, Wang L, Chai ZT, et al. Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling[J]. PLoS One, 2014, 9: e115949.
[38] Yuan HJ, Liu FY, Li X, et al. Clinical efficacy of chemoembo-lization with simultaneous radiofrequency ablation for treatment of adrenal metastases from hepatocellular carcinoma[J]. Cancer Imaging, 2018, 18: 24-24.
[39] Wang WD, Zhang LH, Ni JY, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis[J]. Korean J Radiol, 2018, 19: 613-622.
[40] Zuo MX,Huang JH. The history of interventional therapy for liver cancer in China[J]. J Intervent Med, 2018, 1: 70-76.
[41] Cao JH, Zhou J, Zhang XL, et al. Meta-analysis on radiofre-quency ablation in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. J Huazhong Univ Sci Technolog Med Sci, 2014, 34: 692-700.
[42] 韩 玥, 于 雷, 郝玉芝, 等. 人工胸水技术在经皮射频消融治疗肝脏膈顶肿瘤中的应用[J]. 中华肿瘤杂志, 2012, 34: 846-849.
[43] 周 珍, 刘慧亚, 周 涛, 等. 射频消融联合人工腹水治疗特殊区域肝癌临床观察[J]. 中国现代普通外科进展, 2015, 18: 450-454.
[44] Kondo Y, Yoshida H, Shiina S, et al. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract[J]. Br J Surg, 2006, 93: 1277-1282.
[45] Finn RS. Emerging targeted strategies in advanced hepatocellular carcinoma[J]. Semin Liver Dis, 2013, 33: S11-S19.
[46] Gu FM, Li QL, Gao Q, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3[J]. World J Gastroenterol, 2011, 17: 3922-3932
[47] Li QL, Gu FM, Wang Z, et al. Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma[J]. PLoS One, 2012, 7: e33379.
[48] Spallanzani A, Orsi G, Andrikou K, et al. Lenvatinib as a therapy for unresectable hepatocellular carcinoma[J]. Expert Rev Anticancer Ther, 2018, 18: 1069-1076.
[49] Zhang Q, Kong J, Dong S, et al. Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation[J]. Cancer Cell Int, 2017, 17: 48.
[50] Kumar G, Goldberg SN, Wang Y, et al. Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition[J]. Eur Radiol, 2017, 27: 1238-1247.

相似文献/References:

[1]王建新,许成平,邵亚男,等. 125Ⅰ-LUF体毛导向治疗晚期肝癌初步报告[J].介入放射学杂志,1997,(01):16.
[2]龚承友,初曙光,陈陵际,等.蓖麻蛋白对裸鼠肝癌瘤体内注射的疗效及骨髓抑制的研究[J].介入放射学杂志,1997,(04):219.
[3]马广勤,高从敬,万向荣,等.晚期肝癌变异性、寄生性供血的基础研究[J].介入放射学杂志,1998,(02):95.
[4]刘传方,詹迎江.外生型肝癌三例[J].介入放射学杂志,1998,(03):190.
[5]程红岩,曲增强,徐爱民,等.肝癌介入治疗中预防副反应的初步探讨[J].介入放射学杂志,1998,(03):161.
[6]黄小明,于淼,暴军玲,等.甲氧氯普胺治疗肝癌介入治疗中的胃肠道反应[J].介入放射学杂志,1998,(04):245.
[7]张桂敏,陆翠玉.肝癌介入治疗术后物品的消毒处理[J].介入放射学杂志,1998,(04):244.
[8]杨熙章,吴纪瑞,杨永岩,等.灌注化疗预防肝癌术后复发[J].介入放射学杂志,1999,(02):32.
[9]钟力,夏海平,王吉先,等.肝动脉栓塞化疗结合超声导向注射酒精治疗肝癌的疗效观察[J].介入放射学杂志,1992,(01):48.
[10]李章钧.晚期肝梅毒误为肝癌一例[J].介入放射学杂志,1993,(01):4.

备注/Memo

备注/Memo:
(收稿日期:2018-09-25)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2019-08-21